Since the 1970s, the mortality rate for children and adolescents with cancer has dropped by almost 50%, but the cure rate for pediatric cancer has plateaued in the past several years because there are relatively few new drugs being tested for childhood cancers, says Joseph Simone, M.D., professor emeritus of medicine and pediatrics at the Huntsman Cancer Institute at the University of Utah in Salt Lake City.
The number of cancer cases in children and adolescents each year is small-about 12,500-compared with the number in adults, and drug companies are reluctant to invest money in clinical trials for such a small population. Moreover, it can be difficult to enroll enough patients who meet specific enrollment criteria. When drugs are tested, there is usually a 5-to 10-year gap between the time they reach adults and the time they reach children. "There is a consensus that there won't be a rise in cure rates without new agents," Reaman chalks up the scarcity of pediatric cancer drugs to drug companies' fears of unexpected adverse effects and accompanying bad publicity, as well as the small pediatric market. For Gore, part of the problem lies with the necessary regulatory and ethical guidelines Dr. Frank Balis N E W S that define children as vulnerable research subjects. Drugs need to be tested in adults first to establish safety and tolerability. "This means that by the time a drug reaches pediatric phase I trials, it is likely to be well into phase II and III testing in adults, or even be approved. The last thing we want to do is to rush a drug through, but at the same time, kids are out there dying who don't have to die," Gore said.
FDA Efforts
The U.S. Food and Drug Administration recently instituted two regulatory initiatives to counteract those forces. In January 2002, Congress passed the Best Pharmaceuticals for Children Act, which provides for a 6-month extension of marketing exclusivity for the entire product line of a drug if a sponsor agrees to conduct and submit results of pediatric studies, said Ramzi Dagher,
M.D., medical team leader of the Division of Oncology Drug Products in FDA's Center for Drug Evaluation and Research (CDER).
"Several labeling changes have been made already to some oncology drugs based on studies conducted under these agreements, and there are several other drugs for which studies are being conducted currently and others for which plans are being discussed between sponsors and the FDA," he said. Some are for previously marketed drugs, and some are for recently approved or investigational drugs, Dagher added. This is symptomatic of the larger problem, Gore said. "Vincristine has been used in pediatric oncology since the 1950s and 1960s. It will never be systematically tested because it is considered standard of care for many types of pediatric cancers, and no one would ever go without it in a randomized study. The story with dactinomycin is almost the same. These are old drugs that are important to standard therapy, but studies with them in children would add little to current knowledge," she said. Resources should be devoted to newer agents, she asserted.
"Since the FDA initiatives, the situation has improved somewhat," Adamson said, and others agree. "But the challenges in pediatric oncology are deeper than getting new drugs to trials," he said. "One problem is that there has never been a systematic, forwardlooking preclinical effort to look at new agents," Adamson said.
Preclinical Research
Such a program has just been initiated. On September 30, the NCI approved 5 years of funding to develop preclinical models of childhood cancers to determine which drugs are most likely to be effective to treat them. "Researchers will develop pediatric xenograft models using SCID mice to systematically screen drugs against pediatric tumors, develop in vitro cell lines, mouse models, and test them against a few conventional drugs to calibrate the system and provide a baseline for combination treatments," said Malcolm Smith, M.D., Ph.D., of NCI's CTEP.
Balis is developing microarrays for 17 different childhood tumors and receptors and will screen targeted drugs such as gefitinib and Tarceva (erlotinib) to determine "if it is rational to use them in children."
Gore and Balis both said that the current strategy in cancer drug development-away from random screening and indiscriminate killing of rapidlygrowing and dividing cells and toward targeting proteins at the cellular levelshould guide future testing of pediatric cancer drugs.
"We need better strategies to define the biologic characteristics of patients and tumors for which new therapies are most appropriate, as well as to elucidate mechanisms leading to the malignant phenotype, and novel trial design is needed for the newer, molecular targeted therapies," Gore said.
-Vicki Brower Dr. Gregory Reaman
Pediatric Research Equity Act
The Pediatric Research Equity Act, passed by Congress in 2003, gave the U.S. Food and Drug Administration the authority to require drug manufacturers to perform pediatric testing on certain products.
In October of 2002, a U.S. district court ruled that the FDA lacked sufficient statutory authority to require pediatric studies and prevented FDA from enforcing the requirements that were originally mandated in a 1998 regulation known as the "pediatric rule." After the court ruling, the FDA sought a congressional mandate that would give the agency the authority to require such studies.
The full text of the act is available at http://www.fda.gov/opacom/laws/prea.html.
